Activity of high-dose epirubicin combined with gemcitabine in advanced non-small-cell lung cancer: A multicenter phase I and II study

British Journal of Cancer

Volumn 82, Issue 4, 2000, Pages 806-811

  Van Putten, J W G ^a   Eppinga, P ^b   Erjavec, Z ^c   De Leede, G ^d   Nabers, J ^e   Smeets, J B E ^f   Sleijfer, D Th ^a   Groen, H J M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b NIJ SMELLINGHE HOSPITAL   (Netherlands)

^c Delfzicht Hospital   (Netherlands)

^d Bethesda Hospital   (Netherlands)

^e Medical Center   (Netherlands)

^f Department of Endocrinology   (Netherlands)

Author keywords

Chemotherapy; Epirubicin; Gemcitabine; Non small cell lung cancer

Indexed keywords

EPIRUBICIN; GEMCITABINE;

ADULT; AGED; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE CALCULATION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GRANULOCYTOPENIA; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 0033983673     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.1999.1003     Document Type: Article

References (30)

1. Aaronson NK, Culla, Kaasa S and Sprangers MAG (1994) The EORTC modular approach to quality of life assessment in oncology. Int J Mental Health 23: 75-96
2. Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D and Rugg TA (1994) Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. J Clin Oncol 12: 1535-1540
3. Abratt RP, Bezwoda RW, Goedhals T and Hacking DJ (1997) Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small-cell lung cancer. J Clin Oncol 15: 744-749
4. American Society of Clinical Oncology (1997) Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. J Clin Oncol 15: 2996-3018
5. Anton A, Diaz-Fernandez N, Gonzalez Larriba JL, Vadell C, Masutti B, Montalar J, Barneto I, Artal A and Rosell R (1998) Phase II trial assessing the combination of gemcitabine and cisplatin in advanced non-small-cell lung cancer. Lung Cancer 22: 139-149
6. Bakker M, Groen HJM, Smit EF, Smeets JBE, Riggi M and Postmus PE (1995) Phase I study of high-dose epirubicin and vinorelbine in previously untreated non-small-cell lung cancer stage IIIb-IV. Br J Canc 72: 1547-1550
7. Billingham LJ, Cullen MH, Woods J, Chetiyawardane AD, Joshi RC, Cook J and Woodroffe CM (1998) Mitomycine, ifosfamide and cisplatin in non-small-cell lung cancer: results of a randomized trial evaluating palliation and quality of life. Lung Cancer 18: 9 (abstract 26)
8. Brocato N, Bruno MF, Araujo CE, Cervellino JC, Pirisi C, Temperley G, Sparrow C, Savulsky C and Balbiani LR (1995) Treatment of non-small-cell lung cancer with ifosfamide and epirubicin and platinum versus ifosfamide and epirubicin. Oncology 52: 24-31
9. Bunn PA (1989) The expanding role of cisplatin in the treatment of non-small-cell lung cancer. Semin Oncol 16: 27-33
10. Cardenal F, Paz Lopez-Cabrerizo M, Anton A, Alberola V, Massuti B, Carrato A, Barneto I, Lomas M, Garcia M, Lianes P, Montalar J, Vadell C, Gonzelez-Larriba JL, Nguyen B, Artal A and Rosell R (1999) Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 17: 12-17
11. Crino L, Scagliotti G, Marangolo M, Figoli F, Clerici M, DE Marinis F, Salvati F, Cruciani G, Dogliotti L, Pucci F, Paccagnella A, Adamo V, Altavilla G, Incoronato P, Trippetti M, Mosconi AM, Santucci A, Sorbolini S, Oliva C and Tonato M (1997) Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 15: 297-303.
12. Crino L, Conte P, DE Marinis F, Rinaldi M, Gridelli C, Ceribelli A, Matano E, Marangola M, Bartolucci R, Oliva C, Tonto M, for the Italian Lung Cancer Project (1998) A randomized trial of gemcitabine-cisplatin versus mitomycine, ifosfamide and cisplatin in advanced non-small-cell lung cancer. A multicenter phase III study. Proc Am Soc Clin Oncol 17: 455a (abstract 1750)
13. Cullen MH (1993) The MIC-regimen in non-small-cell lung cancer. Lung Cancer 14: 81-89
14. Feld R, Wierzbicki R, Walde PLD, Shepherd FA, Evans WK, Gupta S, Shannon P and Lassus M (1992) Phase I-II study of high-dose epirubicin in advanced non-small-cell lung cancer. J Clin Oncol 10: 297-303
15. Gatzemeier U, Shepherd FA, LE Chevalier T, Weynants P, Cottier B, Groen HJM, Rosso R, Mattson K, Cortes-Funes H, Tonato M, Burkes RL, Gottfried M and Voi M (1996) Activity of gemcitabine in patients with non-small-cell lung cancer: a multicentre, extended phase II study. Eur J Cancer 32: 243-248
16. Georgoulias V, Kouroussis C, Androlakis N, Kakol Yris S, Dimopoulns MA, Papadakis E, Bouros D, Apostolopoulou F, Papadimitriou C, Agelidou A, Hatzakis K, Kalkabis K, Kotsakis A, Vardakis N and Vlachonicolis J (1999) Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: a multicenler phase II trial. J Clin Oncol 17: 914-920
17. Grant SC, Gralle RJ, Kris MG, Orazen J, Kitsis EA (1992) Single-agent chemotherapy trials in small-cell lung cancer, 1970 to 1990: the case for studies in previously treated patients. J Clin Oncol 10: 484-498
18. Launchbury AP and Habboubi N (1993) Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity. Cancer Treat Rev 19: 197-228
19. Lilenbaum RC, Langenberg P and Dickersin K (1998) Single agent versus combination chemotherapy in patients with advanced non-small-cell lung cancer. Cancer 82: 116-126
20. Marino P, Pampallona S, Preatoni A, Cantoni A and Invernizzi F (1994) Chemotherapy versus supportive care in advanced non-small-cell lung cancer: results of a meta-analysis of the literature. Chest 106: 861-865
21. NSCLC Collaborative Group (1995) Chemotherapy in non-small-cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 311: 899-909
22. Plosker GL and Faulds D (1993) Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy. Drugs 45: 788-856
23. Sandler AB, Ansari R, McClean J, Fisher W, Dorr A and Einhorn LH (1995) A Hoosier Oncology Group phase II study of gemcitabine plus cisplatin in non-small-cell lung cancer. Proc Am Soc Clin Oncol 14: 357 (abstract 1089)
24. Sandler A, Crino L and Steward WP (1996) Extended survival in stage III and IV non-small-cell lung cancer patients treated with gemcitabine plus monthly cisplatin. Ann Oncol 7(suppl 5): 91
25. Sandler A, Nemunaitis J, Dehnam C, Cormier Y, Von Pawel J, Niyikiza C, Nguyen B, Einhorn L and Hoosier Oncology Group (1998) Phase III study of cisplatin with or without gemcitabine in patients with advanced non-small-cell lung cancer. Proc Am Soc Clin Oncol 17: 454a, (abstract 1747)
26. Smit EF, Berendsen HH, Piers DA, Smeets J, Riva A and Postmus PE (1992) A phase II study of high dose epirubicin in unresectable non-small-cell lung cancer. Br J Cancer 65: 405-408
27. Souquet PJ, Chauvin F, Boissel JP, Cellerino R, Cormier Y, Ganz PA, Kaasa S, Pater JL, Quoix E, Rapp E, Tumarello D, Williams J and Bernard JP (1993) Polychemotherapy in advanced non-small-cell lung cancer: a meta-analysis. Lancet 342: 19-21
28. Wilkes JD (1998) Prevention and treatment of oral mucositis following cancer chemotherapy. Semin Oncol 25: 538-551
29. Wils J, Ultama I, Sala L, Smeets J and Riva A (1990) Phase II study of high dose epirubicin in non-small-cell lung cancer. Eur J Cancer 26: 1140-1141
30. Who World Health Organization: (1979) WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland